Mark Heaney

8.3k citations

91 papers · 4.5k indexed · 1 hit paper · h-index 31

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in ⓘ

Genetics 37
- Myeloproliferative Neoplasms: Diagnosis and Treatment 22
- Chronic Lymphocytic Leukemia Research 15
Hematology 27
- Acute Myeloid Leukemia Research 19
- Chronic Myeloid Leukemia Treatments 15

Co-authors: David W. Golde (15 shared papers)Owen A. O’Connor (6 shared papers)David A. Scheinberg (12 shared papers)Jeffrey R. Gardner (12 shared papers)Lawrence B. Schwartz (2 shared papers)Victoria M. Richon (2 shared papers)Paul A. Marks (2 shared papers)William Kevin Kelly (2 shared papers)
Journals: Blood (33 papers)Journal of Clinical Oncology (11 papers)Leukemia Research (4 papers)Cancer (2 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Canada Italy

In The Last Decade

Mark Heaney

90 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer 2005 · 739 citations

Peers

Countries citing papers authored by Mark Heaney

Since Specialization

Citations

This map shows the geographic impact of Mark Heaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Heaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Heaney more than expected).

Fields of papers citing papers by Mark Heaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Heaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Heaney. The network helps show where Mark Heaney may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Heaney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Heaney Line = papers co-authored together Mark Heaney links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer Journal of Clinical Oncology ·William Kevin Kelly, Owen A. O’Connor, Lee M. Krug, Judy H. Chiao, Mark Heaney, Tracy Curley, Barbara MacGregore-Cortelli, William P. Tong, J. Paul Secrist, Lawrence B. Schwartz, Stacy Richardson, Elaina Chu, Semra Olgac, Paul A. Marks, Howard I. Scher, Victoria M. Richon Hit paper breakdown →	2005	739
2	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease Blood ·Eli L. Diamond, Lorenzo Dagna, David M. Hyman, Giulio Cavalli, Filip Jankú, Juvianee Estrada‐Veras, Marina Ferrarini, Omar Abdel‐Wahab, Mark Heaney, Paul J. Scheel, Nancy Feeley, Elisabetta Ferrero, Kenneth L. McClain, Augusto Vaglio, Thomas V. Colby, Laurent Arnaud, Julien Haroche	2014	361
3	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies Journal of Clinical Oncology ·Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Stacie Richardson, Robert D. Willim, Barbara MacGregor‐Cortelli, Tracey Curly, Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria M. Richon, Paul A. Marks, William Kevin Kelly	2005	345
4	Myelodysplasia New England Journal of Medicine ·Mark Heaney, David W. Golde	1999	320
5	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood ·Daniel J. DeAngelo, Richard M. Stone, Mark Heaney, Stephen D. Nimer, Ronald Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nicholas H. G. Holford, Peter Curtin, Brian Druker, Michael C. Heinrich	2006	216
6	Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia Clinical Cancer Research ·Todd Rosenblat, Michael R. McDevitt, Deborah Mulford, Neeta Pandit‐Taskar, Chaitanya Divgi, Katherine S. Panageas, Mark Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic	2010	213
7	Refractory Aspergillus pneumonia in patients with acute leukemia Cancer ·Timothy Aliff, P. Maslak, Joseph G. Jurcic, Mark Heaney, Kathleen N. S. Cathcart, Kent A. Sepkowitz, Mark A. Weiss	2003	172
8	Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs Cancer Research ·Mark Heaney, Jeffrey R. Gardner, Nicos Karasavvas, David W. Golde, David A. Scheinberg, Emily A. Smith, Owen A. O’Connor	2008	169
9	A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia Nucleic Acids Research ·Prabodhika Mallikaratchy, Alessandro Ruggiero, Jeffrey R. Gardner, Vitaly Kuryavyi, William F. Maguire, Mark Heaney, Michael R. McDevitt, Dinshaw J. Patel, David A. Scheinberg	2010	156
10	Soluble receptors in human disease Journal of Leukocyte Biology ·Mark Heaney, David W. Golde	1998	149
11	Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia Journal of Clinical Oncology ·Nicole Lamanna, Matt Kalaycio, P. Maslak, Joseph G. Jurcic, Mark Heaney, Renier J. Brentjens, Andrew D. Zelenetz, Denise Horgan, Alison N. Gencarelli, Katherine S. Panageas, David A. Scheinberg, Mark A. Weiss	2006	121
12	Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma Blood ·Luca Paoluzzi, Mithat Gönen, Jeffrey R. Gardner, Jill Mastrella, Dajun Yang, Jon Holmlund, Mel Sorensen, Lance Leopold, Katia Manova, Guido Marcucci, Mark Heaney, Owen A. O’Connor	2008	118
13	The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies Blood ·Luca Paoluzzi, Mithat Gönen, Govind Bhagat, Richard R. Furman, Jeffrey R. Gardner, Luigi Scotto, Volodia D. Gueorguiev, Mark Heaney, Katia Manova, Owen A. O’Connor	2008	91
14	Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics Journal of Clinical Investigation ·Mona D. Lee, Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, Paula A. Hayes, Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg	2004	89
15	Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics Journal of Clinical Investigation ·Mona D. Lee, Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, Paula A. Hayes, Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg	2004	83
16	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial Blood Advances ·Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Ruben A. Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark Heaney, Casey L. O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann	2020	81
17	N-Glycosylation of the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor α Subunit Is Essential for Ligand Binding and Signal Transduction Journal of Biological Chemistry ·D X Ding, Juan Carlos Vera, Mark Heaney, David W. Golde	1995	59
18	The alpha subunit of the human granulocyte-macrophage colony-stimulating factor receptor signals for glucose transport via a phosphorylation-independent pathway. Proceedings of the National Academy of Sciences ·D X Ding, Coralia I. Rivas, Mark Heaney, M A Raines, Juan Carlos Vera, David W. Golde	1994	56
19	Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses Journal of Clinical Oncology ·Nicole Lamanna, Joseph G. Jurcic, Ariela Noy, P. Maslak, Alison N. Gencarelli, Katherine S. Panageas, Mark Heaney, Renier J. Brentjens, David W. Golde, David A. Scheinberg, Andrew D. Zelenetz, Mark A. Weiss	2008	54
20	Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis Blood ·Priya Koppikar, Omar Abdel‐Wahab, Cyrus V. Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine, Jeffrey R. Gardner, Andrew P. Combs, Kris Vaddi, Patrick J. Haley, Timothy C. Burn, Mark Rupar, Jacqueline Bromberg, Mark Heaney, Elisa de Stanchina, Jordan S. Fridman, Ross L. Levine	2010	54

About Mark Heaney

Mark Heaney is a scholar working on Genetics, Hematology, Immunology, Microbiology and Rheumatology, having authored 91 papers that have together received 4.5k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (19 papers), Chronic Lymphocytic Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (15 papers), Eosinophilic Disorders and Syndromes (10 papers), Immune Response and Inflammation (10 papers), Immunotherapy and Immune Responses (8 papers) and Mast cells and histamine (7 papers). The work is most often cited by research in Hematology (1.0k citations), Genetics (906 citations), Oncology (962 citations), Pathology and Forensic Medicine (626 citations) and Immunology (695 citations). Mark Heaney has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include David W. Golde, Owen A. O’Connor, David A. Scheinberg, Jeffrey R. Gardner, Lawrence B. Schwartz, Victoria M. Richon, Paul A. Marks, William Kevin Kelly, Joseph G. Jurcic and Howard I. Scher. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact